Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety

Overview

This study compares the antihypertensive effects between different treatment groups including antihypertensive drug, anxiolytic, and both, which provide a new clinical evidence for controlling blood pressure in patients with hypertension and anxiety.

Full Title of Study: “Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety: a Multicentre, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 1, 2020

Detailed Description

In recent years, many studies have found that elevated blood pressure is associated with anxiety. It has been report that the incidence of hypertension with anxiety is 25%-54%. The studies have confirmed that anxiety can significantly reduce the antihypertensive effect. Therefore, anxiolytics can increase the antihypertensive effect in patients with hypertension and anxiety. However, there is currently no standard treatment for patients with hypertension and anxiety, and few clinical studies have focused on the treatment of these neglected patients. Improvement on hypertension through relieving anxiety and relief of anxiety through lowering hypertension are lack of clinical studies to prove. This study compares the antihypertensive effects between different treatment groups including antihypertensive drug, anxiolytic, and both, which provide a new clinical evidence for controlling blood pressure in patients with hypertension and anxiety.

Interventions

  • Drug: Tandospirone + Amlodipine
    • The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
  • Drug: Tandospirone placebo + Amlodipine
    • The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
  • Drug: Tandospirone + Amlodipine placebo
    • The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
  • Drug: Tandospirone placebo + Amlodipine placebo
    • The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).

Arms, Groups and Cohorts

  • Experimental: Group 1
    • Tandospirone + Amlodipine
  • Experimental: Group 2
    • Tandospirone placebo + Amlodipine
  • Experimental: Group 3
    • Tandospirone + Amlodipine placebo
  • Placebo Comparator: Group 4
    • Tandospirone placebo + Amlodipine placebo

Clinical Trial Outcome Measures

Primary Measures

  • Office systolic blood pressure and diastolic blood pressure
    • Time Frame: Change from Baseline Office systolic blood pressure and diastolic blood pressure at 4 weeks and 8 weeks
  • 14-item Hamilton Anxiety Scale(HAMA)
    • Time Frame: Change from Baseline HAMA score at 4 weeks and 8 weeks
    • HAMA-14 are rated on 5 grades ranging from 0(no symptom) to 4 (very severe). The total score ranges from 0 to 56. 29 or more on HAMA means severe anxiety disorders, 21 to 28 on HAMA means obvious anxiety disorders, 14 to 20 on HAMA means anxiety disorders, 8 to 13 on HAMA means suspicious anxiety disorders, 7 or less means no anxiety disorders.

Secondary Measures

  • the proportion of patients who met blood pressure control goal( < 140/90mmHg)
    • Time Frame: Week 8
  • 24-hour ambulatory blood pressure monitoring(ABPM)
    • Time Frame: Change from Baseline ABPM at 4 weeks and 8 weeks
  • the proportion of participants with an at least 50% reduction of HAMA score from baseline
    • Time Frame: Week 8
  • the proportion of participants showing 7 or less on HAMA
    • Time Frame: Week 8
  • 20-item Self-Rating Anxiety Scale(SAS)
    • Time Frame: Change from Baseline SAS score at 4 weeks and 8 weeks
    • SAS-20 are rated on 4 grades ranging from 1(a little of the time) to 4(most of the time).The standard score ranges are 25-49 (normal range), 50-59 (mild anxiety), 60-69(moderate anxiety), and 70 or more(severe anxiety).
  • heart rate variability(HRV)
    • Time Frame: Change from Baseline HRV at 4 weeks and 8 weeks
  • 17-item Hamilton Depression Rating Scale(HAMD)
    • Time Frame: Change from Baseline HAMD score at 4 weeks and 8 weeks
    • HAMD-17 are rated on 5 grades ranging from 0 (no symptom) to 4 (very severe). 7 or less on HAMD means no depression, 7 to 17 on HAMD means mild depression, 18 to 23 on HAMD means moderate depression, and 24 or more on HAMD means severe depression.
  • Clinical Global Impression-Improvement(CGI-I)
    • Time Frame: Change from Baseline CGI-I score at 4 weeks and 8 weeks
  • Quality of Life Enjoyment and Satisfaction Questionnaire(Q-LES-Q)
    • Time Frame: Change from Baseline Q-LES-Q score at 4 weeks and 8 weeks
    • Q-LES-Q are rated on 5 grades ranging from 1 to 5 points.

Participating in This Clinical Trial

Inclusion Criteria

1. An age of 60 – 80 years old; 2. Mild or moderate hypertension diagnosed in previous or at screening (office systolic blood pressure ≥ 140 mm Hg and ≤ 180 mm Hg, or diastolic blood pressure ≥ 90 mm Hg and ≤ 110 mm Hg, or both, on three readings on separate days when not taking any blood pressure drugs) ,and the blood pressure still meet the above criteria after the run-in period; 3. A total score ≥ 14 and ≤ 24 on the Hamilton Anxiety Scale (HAMA), except for panic disorder; 4. Informed consent signed. Exclusion Criteria:

1. Secondary hypertension; 2. Office systolic blood pressure ≥ 180 mm Hg or diastolic blood pressure ≤ 110 mm Hg 3. Hypertension with target organ damage; 4. Cerebral hemorrhage, ischemic cerebral infarction, coronary artery disease, myocardial infarction, second-degree or third-degree atrioventricular block, sick sinus syndrome, atrial fibrillation, left ventricular hypertrophy, cardiac insufficiency (NYHA class Ⅱ-Ⅳ); 5. Diabetes and dyslipidemia; 6. Asthma, chronic obstructive pulmonary disease, bronchiectasis, and respiratory failure; 7. Inflammatory bowel disease, active gastritis, pancreatitis, partial or complete intestinal obstruction, and chronic diarrhea; 8. Acute or chronic hepatitis, hepatic insufficiency (ALT or AST is more than 2 times the upper limit of normal), and renal insufficiency (serum creatinine > 130 umol / L); 9. Uncontrolled thyroid diseases; 10. Severe or unstable central nervous system diseases; 11. Schizophrenia, bipolar disorder, severe intellectual disability, or severe cognitive impairment; 12. Having been diagnosed with alcohol or drug abuse within the past 1 year; 13. Presenting the risk of suicide, self-injury, and hurt others; 14. Having participated in other clinical studies within the past 3 months; 15. Having been treated with anxiolytics, antidepressants, antipsychotics within the past 4 weeks, or have contraindications to the study medications. 16. Breastfeeding, pregnancy, or a pregnancy plan during the study; 17. Other diseases which the responsible clinician judged that a change in current therapy would place the participant at risk.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chongqing Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xie Peng, Professor of Neurology, Yongchuan Hospital of Chongqing Medical University – Chongqing Medical University
  • Overall Contact(s)
    • Peng Xie, 86-023-68485490, xiepeng@cqmu.edu.cn

References

Bhattacharya R, Shen C, Sambamoorthi U. Excess risk of chronic physical conditions associated with depression and anxiety. BMC Psychiatry. 2014 Jan 16;14:10. doi: 10.1186/1471-244X-14-10.

Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat. 2015 Apr 22;11:1121-30. doi: 10.2147/NDT.S77710. eCollection 2015.

Byrd JB, Brook RD. Anxiety in the "age of hypertension". Curr Hypertens Rep. 2014 Oct;16(10):486. doi: 10.1007/s11906-014-0486-0.

Kretchy IA, Owusu-Daaku FT, Danquah SA. Mental health in hypertension: assessing symptoms of anxiety, depression and stress on anti-hypertensive medication adherence. Int J Ment Health Syst. 2014 Jun 21;8:25. doi: 10.1186/1752-4458-8-25. eCollection 2014.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.